Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

284 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Additional Candidate Genes for Human Atherosclerotic Disease Identified Through Annotation Based on Chromatin Organization.
Haitjema S, Meddens CA, van der Laan SW, Kofink D, Harakalova M, Tragante V, Foroughi Asl H, van Setten J, Brandt MM, Bis JC, O'Donnell C, Cheng C, Hoefer IE, Waltenberger J, Biessen E, Jukema JW, Doevendans PA, Nieuwenhuis EE, Erdmann J, Björkegren JL, Pasterkamp G, Asselbergs FW, den Ruijter HM, Mokry M. Haitjema S, et al. Among authors: hoefer ie. Circ Cardiovasc Genet. 2017 Apr;10(2):e001664. doi: 10.1161/CIRCGENETICS.116.001664. Circ Cardiovasc Genet. 2017. PMID: 28320757 Free article.
The visualization of the remodelling paradox.
Pasterkamp G, Hoefer I. Pasterkamp G, et al. Eur Heart J. 2008 Jul;29(14):1704-5. doi: 10.1093/eurheartj/ehn201. Epub 2008 Jun 24. Eur Heart J. 2008. PMID: 18577557 No abstract available.
Targeting adhesion molecules in cardiovascular disorders.
Haverslag R, Pasterkamp G, Hoefer IE. Haverslag R, et al. Among authors: hoefer ie. Cardiovasc Hematol Disord Drug Targets. 2008 Dec;8(4):252-60. doi: 10.2174/187152908786786188. Cardiovasc Hematol Disord Drug Targets. 2008. PMID: 19075635 Review.
Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody.
Arslan F, Smeets MB, O'Neill LA, Keogh B, McGuirk P, Timmers L, Tersteeg C, Hoefer IE, Doevendans PA, Pasterkamp G, de Kleijn DP. Arslan F, et al. Among authors: hoefer ie. Circulation. 2010 Jan 5;121(1):80-90. doi: 10.1161/CIRCULATIONAHA.109.880187. Epub 2009 Dec 21. Circulation. 2010. PMID: 20026776
284 results